已关闭
  • 顶部Banner位
  • 固定模块
设置
BPD
试用
AI
企业管理端
厂家
Mucin 16 Rabbit Polyclonal Antibody
收藏 收藏
分享
原料试剂 研发实验室
价格
¥1200.00
品牌 EnkiLife/恩玑
地区 中国,湖北省,武汉市
货号 APRab14240
产地 国产
选择规格
50μL
易享客服
EnkiLife
武汉EnkiLife-log科技有限公司
武汉
营业执照已审核
武汉恩玑生命科技有限公司(EnkiLife)是一家聚焦细胞生物学和免疫学的生物技术企业,致力于为生命科学行业的科研工作者提供高质量的产品和卓越的客户服务。 EnkiLife的产品线包括细胞系、原代细胞、培养基、血清、细胞检测试剂盒、蛋白、抗体、ELISA试剂盒、生化试剂盒等,并提供技术服务与定制开发,全方位满足生命科学行业需求,为您的实验保驾护航! EnkiLife的技术团队凭借在生物科学领域的丰富经验和专业知识,已在公司内部构建了一套完善的技术平台,涵盖细胞培养及检测、蛋白表达、抗体制备以及免疫学等多个关键领域。我们始终秉承严格的质量管理体系,优化生产流程,确保为客户提供高效、精准的技术支持。 展望未来,EnkiLife将继续致力于技术创新,不断丰富和完善我们的技术平台,以更好地满足客户需求,同时不断提升服务水平,确保客户体验的持续优化。我们期待与更多的全球科研工作者携手合作,共同推动生命科学领域的进步与发展。
进入店铺
产品规格 图文详情 技术文档
产品规格
品牌名称
EnkiLife/恩玑
货号
APRab14240
国产/进口
国产
规格
50μL
图文详情

产品概述

产品名称(Product Name)

Mucin 16 Rabbit Polyclonal Antibody

描述(Description)

Rabbit Polyclonal Antibody

宿主(Host)

Rabbit

应用(Application)

WB,IHC

种属反应性(Reactivity)

Human,Rat,Mouse

 

产品性能

偶联物(Conjugation)

Unconjugated

修饰(Modification)

Unmodified

同种型(Isotype)

IgG

克隆(Clonality)

Polyclonal

形式(Form)

Liquid

存放说明(Storage)

Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.

储存溶液(Buffer)

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% New type preservative N.

纯化方式(Purification)

Affinity purification

 

免疫原

免疫原信息(Immunogen Information)

0

基因名(Gene Name)

MUC16

别名(Alternative Names)

MUC16; CA125; Mucin-16; MUC-16; Ovarian cancer-related tumor marker CA125; CA-125; Ovarian carcinoma antigen CA125

基因ID(Gene ID)

94025

蛋白ID(SwissProt ID)

Q8WXI7

 

产品应用

稀释比(Dilution Ratio)

WB 1:500-2000;IHC-p 1:50-300

蛋白分子量(Molecular Weight)

 

研究背景

domain:Composed of three domains, a Ser-, Thr-rich N-terminal domain, a repeated domain containing more than 60 partially conserved tandem repeats of 156 amino acids each (AAs 12061-21862) and a C-terminal transmembrane contain domain with a short cytoplasmic tail.,function:Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces.,induction:Up-regulated in ovarian cancer cells.,miscellaneous:Antigen that is the basis for a widely used serum assay for the monitoring of patients with ovarian epithelial cancer. Due to lack of sensitivity for stage I disease and lack of specificity, it is of little value in the detection of early ovarian cancer. Due to its similarly elevated levels in some nonmalignant conditions, it is not specific enough to be used for population screening.,polymorphism:The number of repeats is highly polymorphic.,PTM:Heavily N-glycosylated; expresses primarily high mannose and complex bisecting type N-linked glycans.,PTM:Heavily O-glycosylated; expresses both type 1 and type 2 core glycans.,PTM:May be phosphorylated. Phosphorylation of the intracellular C-terminal domain may induce proteolytic cleavage and the liberation of the extracellular domain into the extracellular space.,PTM:May contain numerous disulfide bridges. Association of several molecules of the secreted form may occur through interchain disulfide bridges providing an extraordinarily large gel-like matrix in the extracellular space or in the lumen of secretory ducts.,similarity:Contains 14 LRR (leucine-rich) repeats.,similarity:Contains 2 ANK repeats.,similarity:Contains 56 SEA domains.,subcellular location:May be liberated into the extracellular space following the phosphorylation of the intracellular C-terminus which induces the proteolytic cleavage and liberation of the extracellular domain.,subunit:Binds to MSLN. Binding to MSLN mediates heterotypic cell adhesion. This may contribute to the metastasis of ovarian cancer to the peritoneum by initiating cell attachment to the mesothelial epithelium via binding to MSLN.,tissue specificity:Expressed in corneal and conjunctival epithelia (at protein level). Overexpressed in ovarian carcinomas and ovarian low malignant potential (LMP) tumors as compared to the expression in normal ovarian tissue and ovarian adenomas.,domain:Composed of three domains, a Ser-, Thr-rich N-terminal domain, a repeated domain containing more than 60 partially conserved tandem repeats of 156 amino acids each (AAs 12061-21862) and a C-terminal transmembrane contain domain with a short cytoplasmic tail.,function:Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces.,induction:Up-regulated in ovarian cancer cells.,miscellaneous:Antigen that is the basis for a widely used serum assay for the monitoring of patients with ovarian epithelial cancer. Due to lack of sensitivity for stage I disease and lack of specificity, it is of little value in the detection of early ovarian cancer. Due to its similarly elevated levels in some nonmalignant conditions, it is not specific enough to be used for population screening.,polymorphism:The number of repeats is highly polymorphic.,PTM:Heavily N-glycosylated; expresses primarily high mannose and complex bisecting type N-linked glycans.,PTM:Heavily O-glycosylated; expresses both type 1 and type 2 core glycans.,PTM:May be phosphorylated. Phosphorylation of the intracellular C-terminal domain may induce proteolytic cleavage and the liberation of the extracellular domain into the extracellular space.,PTM:May contain numerous disulfide bridges. Association of several molecules of the secreted form may occur through interchain disulfide bridges providing an extraordinarily large gel-like matrix in the extracellular space or in the lumen of secretory ducts.,similarity:Contains 14 LRR (leucine-rich) repeats.,similarity:Contains 2 ANK repeats.,similarity:Contains 56 SEA domains.,subcellular location:May be liberated into the extracellular space following the phosphorylation of the intracellular C-terminus which induces the proteolytic cleavage and liberation of the extracellular domain.,subunit:Binds to MSLN. Binding to MSLN mediates heterotypic cell adhesion. This may contribute to the metastasis of ovarian cancer to the peritoneum by initiating cell attachment to the mesothelial epithelium via binding to MSLN.,tissue specificity:Expressed in corneal and conjunctival epithelia (at protein level). Overexpressed in ovarian carcinomas and ovarian low malignant potential (LMP) tumors as compared to the expression in normal ovarian tissue and ovarian adenomas.,

 

研究领域

技术文档
没有您想要的资料?去索要
返回顶部